DSIP
Nonapeptide naturally found in the brain, studied for effects on sleep. Small double-blind studies in insomniacs gave mixed results, and stress-reducing effects are reported in animal studies.
Regulatory status (as of Sept 2026)
Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. PCAC did not recommend it for the 503A Bulks List; vote 6–7–1 (yes–no–abstain), July 24, 2026. No further FDA action as of Sept 17, 2026.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote4 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
DSIP (Delta Sleep-Inducing Peptide) is a compound with only early, small human studies so far. Nonapeptide naturally found in the brain, studied for effects on sleep.
| Half-life | 4.0 ± 0.7 min (dogs, IV) details4.0 ± 0.7 min (dogs, i.v.); 2.9 min (monkey, i.v.); 2.0 min (rats, i.v.) (Kato 1984) |
|---|---|
| How it's given in studies | Subcutaneous or intranasal |
| Research stage | Phase 1 / early human |
| Dosing | Published research: Chronic insomnia patients: 25 nmol/kg IV in the afternoon or evening for 3-4 nights detailsChronic insomnia patients: 25 nmol/kg i.v. in the afternoon or evening for 3-4 nights (Schneider-Helmert-type double-blind studies, 1987 and 1992). That is roughly 20 µg/kg, about 1.4 mg i.v. for 70 kg. Animal studies used i.v., i.c.v. and s.c. routes.Community-reportedCommunity-reported: 100–250 mcg before bed, subcutaneous or intranasal |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is a brain peptide that animal research links to sleep and stress hormones; human sleep studies had mixed results. Proposed mechanism, largely from animal research: besides species-specific effects on sleep, DSIP has been reported to act on circadian locomotor rhythms, brain transmitter concentrations and cortisol levels (review, Schoenenberger 1984). In small double-blind studies of chronic insomniac patients, effects on sleep were mixed (Monti 1987; Bes 1992).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedSome users report running DSIP (Delta Sleep-Inducing Peptide) at 100–250 mcg before bed (subcutaneous or intranasal). This is not a recommendation.
Side effects reported in studies are listed separately below.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
This peptide belongs to the Sleep category. View All Sleep Peptides
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.